Elevance Health Inc. (ELV) stock analysis and fair value
ELV · NYSE · Healthcare
438,47 US$
▲ +1,92%
Cerne score
Fair
- Quality47
- Growth48
- Financial strength26
- Valuation58
- Dividends83
In 30 seconds
The business. Healthcare. Sells 199,1 B US$ a year, keeps 3% as profit and sales grow 10,3% a year (last 5 years).
The price. At its usual price: you pay 17x earnings, close to its normal (19x).
Strength. Passes 6 of 8 quality checks, but debt weighs: 4,2 years of profit.
ELV fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueElevance Health Inc. key numbers
- Market cap
- 95,1 B US$
- P/E (price ÷ earnings)
- 17,5
- Dividend yield
- 1,57%
- Revenue growth
- 9,9%
- a year, over 9 years
- Profit margin
- 2,8%
- Quality checks
- 6/8
Fiscal 2025 financials, as filed with the SEC.
What analysts say
Buy
15 of 23 analysts recommend buying. Average price target: 448,73 US$.
About Elevance Health Inc.
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
See everything about ELV on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector